IFM Investors Pty Ltd Has $6.55 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

IFM Investors Pty Ltd lifted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 10.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,176 shares of the medical research company's stock after buying an additional 3,523 shares during the period. IFM Investors Pty Ltd's holdings in IQVIA were worth $6,554,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in IQV. Calamos Advisors LLC boosted its stake in IQVIA by 33.9% in the 1st quarter. Calamos Advisors LLC now owns 79,266 shares of the medical research company's stock worth $13,975,000 after purchasing an additional 20,071 shares during the period. Goelzer Investment Management Inc. boosted its stake in IQVIA by 1.0% in the 1st quarter. Goelzer Investment Management Inc. now owns 19,950 shares of the medical research company's stock worth $3,517,000 after purchasing an additional 196 shares during the period. Mutual Advisors LLC boosted its stake in IQVIA by 85.1% in the 1st quarter. Mutual Advisors LLC now owns 3,126 shares of the medical research company's stock worth $551,000 after purchasing an additional 1,437 shares during the period. Teacher Retirement System of Texas boosted its stake in IQVIA by 201.6% in the 1st quarter. Teacher Retirement System of Texas now owns 32,432 shares of the medical research company's stock worth $5,718,000 after purchasing an additional 21,679 shares during the period. Finally, Private Trust Co. NA boosted its stake in IQVIA by 22.4% in the 1st quarter. Private Trust Co. NA now owns 536 shares of the medical research company's stock worth $94,000 after purchasing an additional 98 shares during the period. Institutional investors own 89.62% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on IQV shares. Barclays cut their target price on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 7th. Hsbc Global Res downgraded shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Mizuho cut their target price on shares of IQVIA from $210.00 to $190.00 and set an "outperform" rating for the company in a research note on Thursday, May 15th. Finally, HSBC downgraded shares of IQVIA from a "buy" rating to a "hold" rating and cut their target price for the company from $260.00 to $160.00 in a research note on Friday, April 25th. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $226.32.

IQVIA Stock Performance

Shares of IQV traded up $2.24 during mid-day trading on Tuesday, hitting $164.69. 1,987,611 shares of the company's stock were exchanged, compared to its average volume of 1,655,470. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The stock's 50-day simple moving average is $151.11 and its 200-day simple moving average is $172.79. The firm has a market cap of $28.49 billion, a price-to-earnings ratio of 22.44, a price-to-earnings-growth ratio of 1.80 and a beta of 1.30. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 2.19.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The company had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. During the same period last year, the firm earned $2.54 earnings per share. The business's revenue for the quarter was up 2.5% on a year-over-year basis. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.